CHANTIX PATCH (TRANSDERMAL SYSTEM FOR VARENICLINE)
Pfizer Global Research and Development has submitted a patent for a varenicline transdermal patch that would hopefully hit the market in 2008.

Varenicline is a highly potent compound such that dosage forms are necessarily highly diluted with excipients...providing for such desirable features as controlling the drug dissolution...either fast dissolving or slow dissolving in a controlled-release system as described in co-pending applications U.S. Patent Publication No. 2003-0180360 A1 , published Sept. 25, 2003, and Serial No. 10/848,464, filed May 18, 2004.[...]

There are advantages of delivering varenicline in the form of a transdermal composition.

1. Relative to an oral dosage form such as a tablet or capsule delivery of varenicline via a transdermal composition would be a preferred choice by patients who have difficulty in swallowing tablets, capsules or other solids.
2. The tablet dosage form of varenicline has shown, in some instances, a certain level of nausea in patients. There is a need to reduce these side effects.
3. A gradual release of the varenicline dosage form such as would be the case from a transdermal composition might prove to be useful towards reducing the incidence of nausea and enhance the desirability of the drug to a larger patient population requiring its use.
4. Finally, it is likely to assume there would be a higher compliance rate if a patient could apply a transdermal patch that delivers therapeutically useful levels of active ingredient over the course of a day or a longer period of time versus taking a once or twice daily tablet or capsule with water.
   

Accordingly, there is a need for providing transdermal dosage forms of varenicline.

• *How Does Chantix Work? Common Side Effects?*
• *Chantix Testimonials*
• *The Easy Way to Stop Smoking: Join the Millions Who Have Become Nonsmokers Using the Easyway Method*